<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcpediatr&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Pediatrics - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcpediatr/</link>
        <description>The most accessed research articles published by BMC Pediatrics</description>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/66" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/3/13" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/21" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/69" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/67" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/68" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/62" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/7/36" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/9/70" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2431/8/14" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/66">
        <title>The relationship of bottle feeding and other sucking behaviors with speech disorder in Patagonian preschoolers</title>
        <description>Background:
Previous studies have shown that children&apos;s nonnutritive sucking habits may lead to delayed development of their oral anatomy and functioning. However, these findings were inconsistent. We investigated associations between use of bottles, pacifiers, and other sucking behaviors with speech disorders in children attending three preschools in Punta Arenas (Patagonia), Chile.
Methods:
Information on infant feeding and sucking behaviors, age starting and stopping breast- and bottle-feeding, pacifier use, and other sucking behaviors, was collected from self-administered questionnaires completed by parents. Evaluation of speech problems was conducted at preschools with subsequent scoring by a licensed speech pathologist using age-normative standards.
Results:
A total of 128 three- to five-year olds were assessed, 46% girls and 54% boys. Children were breastfed for an average of 25.2 (SD 9.6) months and used a bottle 24.4 (SD 15.2) months. Fifty-three children (41.7%) had or currently used a pacifier for an average of 11.4 (SD 17.3) months; 23 children (18.3%) were reported to have sucked their fingers. Delayed use of a bottle until after 9 months appeared to be protective for subsequent speech disorders. There was less than a one-third lower relative odds of subsequent speech disorders for children with a delayed use of a bottle compared to children without a delayed use of a bottle (OR: 0.32, 95% CI: 0.10-0.98). A three-fold increase in relative odds of speech disorder was found for finger-sucking behavior (OR: 2.99, 95% CI: 1.10-8.00) and for use of a pacifier for 3 or more years (OR: 3.42, 95% CI: 1.08-10.81).
Conclusion:
The results suggest extended use of sucking outside of breastfeeding may have detrimental effects on speech development in young children.</description>
        <link>http://www.biomedcentral.com/1471-2431/9/66</link>
                <dc:creator>Clarita Barbosa</dc:creator>
                <dc:creator>Sandra Vasquez</dc:creator>
                <dc:creator>Mary Parada</dc:creator>
                <dc:creator>Juan Carlos Velez Gonzalez</dc:creator>
                <dc:creator>Chanaye Jackson</dc:creator>
                <dc:creator>N. David Yanez</dc:creator>
                <dc:creator>Bizu Gelaye</dc:creator>
                <dc:creator>Annette Fitzpatrick</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:66</dc:source>
        <dc:date>2009-10-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-66</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>66</prism:startingPage>
        <prism:publicationDate>2009-10-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/3/13">
        <title>A new growth chart for preterm babies: Babson and Benda&apos;s chart updated with recent data and a new format</title>
        <description>Background:
The Babson and Benda 1976 &quot;fetal-infant growth graph&quot; for preterm infants is commonly used in neonatal intensive care. Its limits include the small sample size which provides low confidence in the extremes of the data, the 26 weeks start and the 500 gram graph increments. The purpose of this study was to develop an updated growth chart beginning at 22 weeks based on a meta-analysis of published reference studies.
Methods:
The literature was searched from 1980 to 2002 for more recent data to complete the pre and post term sections of the chart. Data were selected from population studies with large sample sizes. Comparisons were made between the new chart and the Babson and Benda graph. To validate the growth chart the growth results from the National Institute of Child Health and Human Development Neonatal Research Network (NICHD) were superimposed on the new chart.
Results:
The new data produced curves that generally followed patterns similar to the old growth graph. Mean differences between the curves of the two charts reached statistical significance after term. Babson&apos;s 10th percentiles fell between the new data percentiles: the 5th to 17th for weight, the 5th and 15th for head circumference, and the 6th and 16th for length. The growth patterns of the NICHD infants deviated away from the curves of the chart in the first weeks after birth. When the infants reached an average weight of 2 kilograms, those with a birthweight in the range of 700 to 1000 grams had achieved greater than the 10th percentile on average for head growth, but remained below the 3rd percentile for weight and length.
Conclusion:
The updated growth chart allows a comparison of an infant&apos;s growth first with the fetus as early as 22 weeks and then with the term infant to 10 weeks. Comparison of the size of the NICHD infants at a weight of 2 kilograms provides evidence that on average preterm infants are growth retarded with respect to weight and length while their head size has caught up to birth percentiles. As with all meta-analyses, the validity of this growth chart is limited by the heterogeneity of the data sources. Further validation is needed to illustrate the growth patterns of preterm infants to older ages.</description>
        <link>http://www.biomedcentral.com/1471-2431/3/13</link>
                <dc:creator>Tanis Fenton</dc:creator>
                <dc:source>BMC Pediatrics 2003, 3:13</dc:source>
        <dc:date>2003-12-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-3-13</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>3</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2003-12-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/21">
        <title>Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial</title>
        <description>Background:
Several uncontrolled studies of hyperbaric treatment in children with autism have reported clinical improvements; however, this treatment has not been evaluated to date with a controlled study. We performed a multicenter, randomized, double-blind, controlled trial to assess the efficacy of hyperbaric treatment in children with autism.
Methods:
62 children with autism recruited from 6 centers, ages 2&#8211;7 years (mean 4.92 &#177; 1.21), were randomly assigned to 40 hourly treatments of either hyperbaric treatment at 1.3 atmosphere (atm) and 24% oxygen (&quot;treatment group&quot;, n = 33) or slightly pressurized room air at 1.03 atm and 21% oxygen (&quot;control group&quot;, n = 29). Outcome measures included Clinical Global Impression (CGI) scale, Aberrant Behavior Checklist (ABC), and Autism Treatment Evaluation Checklist (ATEC).
Results:
After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p &lt; 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as &quot;very much improved&quot; or &quot;much improved&quot; compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024). Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322). On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p &lt; 0.03 for each), but not in the control group. In the treatment group compared to the control group, mean changes on the ABC total score and subscales were similar except a greater number of children improved in irritability (p = 0.0311). On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group. Post-hoc analysis indicated that children over age 5 and children with lower initial autism severity had the most robust improvements. Hyperbaric treatment was safe and well-tolerated.
Conclusion:
Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.Trial Registrationclinicaltrials.gov NCT00335790</description>
        <link>http://www.biomedcentral.com/1471-2431/9/21</link>
                <dc:creator>Daniel Rossignol</dc:creator>
                <dc:creator>Lanier Rossignol</dc:creator>
                <dc:creator>Scott Smith</dc:creator>
                <dc:creator>Cindy Schneider</dc:creator>
                <dc:creator>Sally Logerquist</dc:creator>
                <dc:creator>Anju Usman</dc:creator>
                <dc:creator>Jim Neubrander</dc:creator>
                <dc:creator>Eric Madren</dc:creator>
                <dc:creator>Gregg Hintz</dc:creator>
                <dc:creator>Barry Grushkin</dc:creator>
                <dc:creator>Elizabeth Mumper</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:21</dc:source>
        <dc:date>2009-03-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-21</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2009-03-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/69">
        <title>&quot;Why do paediatricians prescribe antibiotics? Results of an Italian regional project&quot;</title>
        <description>Background:
To investigate determinants of antibiotic prescription in paediatric care, as a first step of a multilevel intervention to improve prescribing for common respiratory tract infections (RTIs) in a northern Italian region with high antibiotic prescription rate.
Methods:
A two-step survey was performed: in phase I, knowledge, and attitudes were explored involving all family and hospital paediatricians of Emilia-Romagna and a sample of parents. In phase II, patient care practices were explored in a stratified random sample of visits, both in hospitals and family physician&apos;s clinics; parent expectations were investigated in a sub-sample of these visits.
Results:
Out of overall 4352 visits for suspected RTIs, in 38% of children an antibiotic was prescribed. Diagnostic uncertainty was perceived by paediatricians as the most frequent cause of inappropriate prescription (56% of 633 interviewed paediatricians); but, rapid antigen detecting tests was used in case of pharyngitis/pharyngotonsillitis by 36% and 21% of family and hospital paediatricians only. More than 50% of paediatricians affirmed to not adopt a &quot;wait and see strategy&quot; in acute otitis. The perceived parental expectation of antibiotics was not indicated by paediatricians as a crucial determinant of prescription, but this perception was the second factor most strongly associated to prescription (OR = 12.8; 95% CI 10.4 - 15.8), the first being the presence of othorrea. Regarding parents, the most important identified factors, potentially associated to overprescribing, were the lack of knowledge of RTIs and antibiotics (41% of 1029 parents indicated bacteria as a possible cause of common cold), and the propensity to seek medical care for trivial infections (48% of 4352 children accessing ambulatory practice presented only symptoms of common cold).
Conclusion:
A wide gap between perceived and real determinants of antibiotic prescription exists. This can promote antibiotic overuse. Inadequate parental knowledge can also induce inappropriate prescription. The value of this study is that it simultaneously explored determinants of antimicrobial prescribing in an entire region involving both professionals and parents.</description>
        <link>http://www.biomedcentral.com/1471-2431/9/69</link>
                <dc:creator>Maria Luisa Moro</dc:creator>
                <dc:creator>Massimiliano Marchi</dc:creator>
                <dc:creator>Carlo Gagliotti</dc:creator>
                <dc:creator>Simona Di Mario</dc:creator>
                <dc:creator>Davide Resi</dc:creator>
                <dc:creator>Progetto Bambini e Antibiotici Regional Group [ProBA] Group</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:69</dc:source>
        <dc:date>2009-11-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-69</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>69</prism:startingPage>
        <prism:publicationDate>2009-11-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/67">
        <title>Impact of 4.0% chlorhexidine cleansing of the umbilical cord on mortality and omphalitis among newborns of Sylhet, Bangladesh: design of a community-based cluster randomized trial</title>
        <description>Background:
The World Health Organization recommends dry cord care for newborns but this recommendation may not be optimal in low resource settings where most births take place in an unclean environment and infections account for up to half of neonatal deaths. A previous trial in Nepal indicated that umbilical cord cleansing with 4.0% chlorhexidine could substantially reduce mortality and omphalitis risk, but policy changes await additional community-based data.
Methods:
The Projahnmo Chlorhexidine study was a three-year, cluster-randomized, community-based trial to assess the impact of three cord care regimens on neonatal mortality and omphalitis. Women were recruited mid-pregnancy, received a basic package of maternal and neonatal health promotion messages, and were followed to pregnancy outcome. Newborns were visited at home by local village-based workers whose areas were randomized to either 1) single- or 2) 7-day cord cleansing with 4.0% chlorhexidine, or 3) promotion of dry cord care as recommended by WHO. All mothers received basic messages regarding hand-washing, clean cord cutting, and avoidance of harmful home-base applications to the cord. Death within 28 days and omphalitis were the primary outcomes; these were monitored directly through home visits by community health workers on days 1, 3, 6, 9, 15, and 28 after birth.DiscussionDue to report in early 2010, the Projahnmo Chlorhexidine Study examines the impact of multiple or single chlorhexidine cleansing of the cord on neonatal mortality and omphalitis among newborns of rural Sylhet District, Bangladesh. The results of this trial will be interpreted in conjunction with a similarly designed trial previously conducted in Nepal, and will have implications for policy guidelines for optimal cord care of newborns in low resource settings in Asia.Trial RegistrationClinicalTrials.gov (NCT00434408)</description>
        <link>http://www.biomedcentral.com/1471-2431/9/67</link>
                <dc:creator>Luke Mullany</dc:creator>
                <dc:creator>Shams El Arifeen</dc:creator>
                <dc:creator>Peter Winch</dc:creator>
                <dc:creator>Rasheduzzaman Shah</dc:creator>
                <dc:creator>Ishtiaq Mannan</dc:creator>
                <dc:creator>Syed Rahman</dc:creator>
                <dc:creator>Mohammad Rahman</dc:creator>
                <dc:creator>Gary Darmstadt</dc:creator>
                <dc:creator>Saifuddin Ahmed</dc:creator>
                <dc:creator>Mathuram Santosham</dc:creator>
                <dc:creator>Robert Black</dc:creator>
                <dc:creator>Abdullah Baqui</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:67</dc:source>
        <dc:date>2009-10-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-67</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>67</prism:startingPage>
        <prism:publicationDate>2009-10-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/68">
        <title>Health related quality of life of Dutch children: psychometric properties of the PedsQL in the Netherlands </title>
        <description>Background:
Knowledge about psychometric properties of the Pediatric Quality of Life Inventory (PedsQL) in the Netherlands is limited and Dutch reference data are lacking. Aim of the current study is to collect Dutch reference data of the PedsQL and subsequently assess reliability, socio-demographic within-group differences and construct validity.
Methods:
In this study the PedsQL was administered to Dutch children aged 5 to 18 years. A socio-demographic questionnaire was completed as well. The sample consisted of three age groups: 5-7 years (parent proxy report), 8-12 years and 13-18 years (child self report). Analysis was performed with SPSS 16.0.2. A reliability analysis was done using Cronbach&apos;s alpha coefficient. Socio-demographic within-group differences were assessed by means of an ANOVA with post hoc Bonferroni correction and t-tests. Subsequently, construct validity was determined by t-tests and effect sizes.
Results:
For 496 children PedsQL reference data were collected. PedsQL total scores were 84.18 (group 5-7), 82.11 (group 8-12) and 82.24 (group 13-18). Internal consistency coefficients ranged from .53 to .85. Socio-demographic within-group differences demonstrated that, in group 8-12, children of parents born in the Netherlands had significantly lower scores on several PedsQL subscales, compared to children of parents born in another country. With respect to construct validity, healthy children of group 5-7 and 13-18 scored significantly higher than children with a chronic health condition on all subscales, except for emotional functioning. In group 5-7, the PedsQL total score for healthy children was 85.31, whereas the same age group with a chronic health condition scored 78.80. Effect sizes in this group varied from 0.58 to 0.88. With respect to group 13-18, healthy children obtained a PedsQL total score of 83.14 and children suffering from a chronic health condition 77.09. Effect sizes in this group varied from 0.45 to 0.67. No significant differences were found in group 8-12 regarding health.
Conclusion:
The Dutch version of the PedsQL has adequate psychometric properties and can be used as a health related quality of life instrument in paediatric research in the Netherlands.</description>
        <link>http://www.biomedcentral.com/1471-2431/9/68</link>
                <dc:creator>Vivian Engelen</dc:creator>
                <dc:creator>Marleen Haentjens</dc:creator>
                <dc:creator>Symone Detmar</dc:creator>
                <dc:creator>Hendrik Koopman</dc:creator>
                <dc:creator>Martha Grootenhuis</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:68</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-68</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>68</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/62">
        <title>Experiences of integrated management of childhood illness(IMCI) training and implementation in South Africa; a qualitative evaluation of the IMCI case management training course</title>
        <description>Background:
Integrated Management of Childhood Illness (IMCI) is a strategy to reduce mortality and morbidity in children under-5 years by improving management of common illnesses at primary level. IMCI has been shown to improve health worker performance, but constraints have been identified in achieving sufficient coverage to improve child survival, and implementation remains sub-optimal. At the core of the IMCI strategy is a clinical guideline whereby health workers use a series of algorithms to assess and manage a sick child, and give counselling to carers. IMCI is taught using a structured 11-day training course that combines classroom work with clinical practise; a variety of training techniques are used, supported by comprehensive training materials and detailed instructions for facilitators.
Methods:
We conducted focus group discussions with IMCI trained health workers to explore their experiences of the methodology and content of the IMCI training course, whether they thought they gained the skills required for implementation, and their experiences of follow-up visits.
Results:
Health workers found the training interesting, informative and empowering, and there was consensus that it improved their skills in managing sick children. They appreciated the variety of learning methods employed, and felt that repetition was important to reinforce knowledge and skills. Facilitators were rated highly for their knowledge and commitment, as well as their ability to identify problems and help participants as required. However, health workers felt strongly that the training time was too short to acquire skills in all areas of IMCI. Their increased confidence in managing sick children was identified by health workers as an enabling factor for IMCI implementation in the workplace, but additional time required for IMCI consultations was expressed as a major barrier. Although follow-up visits were described as very helpful, these were often delayed and there was no ongoing clinical supervision.
Conclusion:
The IMCI training course was reported to be an effective method of acquiring skills, but more time is required, either during the course, or with follow-up, to improve IMCI implementation. Innovative solutions may be required to ensure that adequate skills are acquired and maintained.</description>
        <link>http://www.biomedcentral.com/1471-2431/9/62</link>
                <dc:creator>Christiane Horwood</dc:creator>
                <dc:creator>Anna Voce</dc:creator>
                <dc:creator>Kerry Vermaak</dc:creator>
                <dc:creator>Nigel Rollins</dc:creator>
                <dc:creator>Shamim Qazi</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:62</dc:source>
        <dc:date>2009-10-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-62</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>62</prism:startingPage>
        <prism:publicationDate>2009-10-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/7/36">
        <title>The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study</title>
        <description>Background:
Recently, hyperbaric oxygen therapy (HBOT) has increased in popularity as a treatment for autism. Numerous studies document oxidative stress and inflammation in individuals with autism; both of these conditions have demonstrated improvement with HBOT, along with enhancement of neurological function and cognitive performance. In this study, children with autism were treated with HBOT at atmospheric pressures and oxygen concentrations in current use for this condition. Changes in markers of oxidative stress and inflammation were measured. The children were evaluated to determine clinical effects and safety.
Methods:
Eighteen children with autism, ages 3&#8211;16 years, underwent 40 hyperbaric sessions of 45 minutes duration each at either 1.5 atmospheres (atm) and 100% oxygen, or at 1.3 atm and 24% oxygen. Measurements of C-reactive protein (CRP) and markers of oxidative stress, including plasma oxidized glutathione (GSSG), were assessed by fasting blood draws collected before and after the 40 treatments. Changes in clinical symptoms, as rated by parents, were also assessed. The children were closely monitored for potential adverse effects.
Results:
At the endpoint of 40 hyperbaric sessions, neither group demonstrated statistically significant changes in mean plasma GSSG levels, indicating intracellular oxidative stress appears unaffected by either regimen. A trend towards improvement in mean CRP was present in both groups; the largest improvements were observed in children with initially higher elevations in CRP. When all 18 children were pooled, a significant improvement in CRP was found (p = 0.021). Pre- and post-parental observations indicated statistically significant improvements in both groups, including motivation, speech, and cognitive awareness (p &lt; 0.05). No major adverse events were observed.
Conclusion:
In this prospective pilot study of children with autism, HBOT at a maximum pressure of 1.5 atm with up to 100% oxygen was safe and well tolerated. HBOT did not appreciably worsen oxidative stress and significantly decreased inflammation as measured by CRP levels. Parental observations support anecdotal accounts of improvement in several domains of autism. However, since this was an open-label study, definitive statements regarding the efficacy of HBOT for the treatment of individuals with autism must await results from double-blind, controlled trials.Trial Registrationclinicaltrials.gov NCT00324909</description>
        <link>http://www.biomedcentral.com/1471-2431/7/36</link>
                <dc:creator>Daniel Rossignol</dc:creator>
                <dc:creator>Lanier Rossignol</dc:creator>
                <dc:creator>S. Jill James</dc:creator>
                <dc:creator>Stepan Melnyk</dc:creator>
                <dc:creator>Elizabeth Mumper</dc:creator>
                <dc:source>BMC Pediatrics 2007, 7:36</dc:source>
        <dc:date>2007-11-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-7-36</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2007-11-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/9/70">
        <title>Comparison of a new transcutaneous bilirubinometer (Bilimed(R)) with serum bilirubin measurements in preterm and full-term infants</title>
        <description>Background:
The gold standard to assess hyperbilirubinemia in neonates remains the serum bilirubin measurement. Unfortunately, this is invasive, painful, and costly. Bilimed (R), a new transcutaneous bilirubinometer, suggests more accuracy compared to the existing non-invasive bilirubinometers because of its new technology. It furthermore takes into account different skin colours. No contact with the skin is needed during measurement, no additional material costs occur. Our aim was to assess the agreement between the Bilimed (R) and serum bilirubin in preterm and term infants of different skin colours.
Methods:
The transcutaneous bilirubin measurements were performed on the infant&apos;s sternum and serum bilirubin was determined simultaneously. The agreement between both methods was assessed by Pearson`s correlation and by Bland-Altman analysis.
Results:
A total of 117 measurement cycles were performed in 99 term infants (group 1), further 47 measurements in 38 preterm infants born between 34 - 36 6/7 gestational weeks (group 2), and finally 21 measurements in 13 preterm infants born between 28 - 33 6/7 gestational weeks (group 3). The mean deviation and variability (+/-2SD) of the transcutaneous from serum bilirubin were: -14 (+/-144) umol/l ;-0.82 (+/-8.4) mg/dl in group 1, +16 (+/-91) umol/l;+0.93(+/-5.3) mg/dl in group 2 and -8 (+/-76) umol/l; -0.47 (+/-4.4) mg/dl in group 3. These limits of agreement are too wide to be acceptable in a clinical setting. Moreover, there was to be a trend towards less good agreement with increasing bilirubin values.
Conclusion:
Despite its new technology the Bilimed(R) has no advantages, and more specifically no better agreement not only in term and near-term Caucasian infants, but also in non-Caucasian and more premature infants.</description>
        <link>http://www.biomedcentral.com/1471-2431/9/70</link>
                <dc:creator>Tanja Karen</dc:creator>
                <dc:creator>Hans Ulrich Bucher</dc:creator>
                <dc:creator>Jean-Claude Fauchere</dc:creator>
                <dc:source>BMC Pediatrics 2009, 9:70</dc:source>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-9-70</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>70</prism:startingPage>
        <prism:publicationDate>2009-11-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2431/8/14">
        <title>Effectiveness of physical therapy interventions for children with cerebral palsy: a systematic review</title>
        <description>Background:
To assess the effectiveness of physical therapy (PT) interventions on functioning in children with cerebral palsy (CP).
Methods:
A search was made in Medline, Cinahl, PEDro and the Cochrane library for the period 1990 to February 2007. Only randomized controlled trials (RCTs) on PT interventions in children with diagnosed CP were included. Two reviewers independently assessed the methodological quality and extracted the data. The outcomes measured in the trials were classified using the International Classification of Functioning, Disability and Health (ICF).
Results:
Twenty-two trials were identified. Eight intervention categories were distinguished. Four trials were of high methodological quality. Moderate evidence of effectiveness was established for two intervention categories: effectiveness of upper extremity treatments on attained goals and active supination, and of prehensile hand treatment and neurodevelopmental therapy (NDT) or NDT twice a week on developmental status, and of constraint-induced therapy on amount and quality of hand use. Moderate evidence of ineffectiveness was found of strength training on walking speed and stride length. Conflicting evidence was found for strength training on gross motor function. For the other intervention categories the evidence was limited due to low methodological quality and the statistically insignificant results of the studies.
Conclusion:
Due to limitations in methodological quality and variations in population, interventions and outcomes, mostly limited evidence on the effectiveness of most PT interventions is available through RCTs. Moderate evidence was found for some effectiveness of upper extremity training. Well-designed trials are needed especially for focused PT interventions.</description>
        <link>http://www.biomedcentral.com/1471-2431/8/14</link>
                <dc:creator>Heidi Anttila</dc:creator>
                <dc:creator>Ilona Autti-Ramo</dc:creator>
                <dc:creator>Jutta Suoranta</dc:creator>
                <dc:creator>Marjukka Makela</dc:creator>
                <dc:creator>Antti Malmivaara</dc:creator>
                <dc:source>BMC Pediatrics 2008, 8:14</dc:source>
        <dc:date>2008-04-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2431-8-14</dc:identifier>
        <prism:publicationName>BMC Pediatrics</prism:publicationName>
        <prism:issn>1471-2431</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2008-04-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
